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I n 2005,  a syndrome of memory deficits,  psychiat-ric symptoms,  decreased consciousness,  and 
hypoventilation in four young women with ovarian 
teratomas was reported [1].  In 2007,  Dalmau and col-
leagues reported that specific autoantibodies to the 
N-methyl D-aspartate receptor (NMDAR) were detected 
in twelve patients,  who had similar neurological symp-
toms,  such as psychosis,  memory deficits,  seizures,  
dyskinesia,  decreased consciousness,  and autonomic 
instability [2].  Of these patients,  seven had ovarian 
teratomas.  The authors coined the term ‘anti-NMDAR 
encephalitis’,  which was initially considered to be a 
paraneoplastic encephalitis [2].  A further study by the 
same authors revealed that most cases of anti-NMDAR 
encephalitis affected children and young adults with or 
without an associated tumor [3].  Since then,  the num-
ber of reported cases of anti-NMDAR encephalitis has 
rapidly increased.  One hundred cases were reported in 
2008 [4],  419 cases in 2011 [3],  and a long-term prog-
nosis survey of 577 cases was reported in 2013 [5].  A 
systematic review summarized the clinical symptoms of 
633 patients with anti-NMDAR encephalitis in 2018 
[6].
Anti-NMDAR encephalitis can be misdiagnosed as 
other psychiatric disorders,  because many patients 
present with prominent psychiatric symptoms,  includ-
ing anxiety,  agitation,  depression,  manic,  bizarre 
behavior,  delusional or paranoid thoughts,  and visual 
or auditory hallucinations [4 , 6 , 7].  Some patients who 
had anti-NMDAR antibodies at the initial diagnosis of 
schizophrenia were reported [8 , 9].  We have also found 
that anti-inflammatory therapy and immunotherapy 
were effective in a patient with anti-NMDAR antibodies 
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who had been initially diagnosed with treatment-resis-
tant schizophrenia [10].  The main presentations of 
atypical anti-NMDAR encephalitis could be psychiatric 
or cognitive symptoms,  without showing either sei-
zures,  involuntary movements,  hypoventilation,  or 
associated tumors [11].
In this review,  we present the mechanisms,  epide-
miology,  symptoms and clinical courses,  diagnostic 
tests,  treatment and outcomes of patients with anti-
NMDAR encephalitis from the perspective of psychia-
try.  We also discuss the diversity in clinical symptoms 
of anti-NMDAR encephalitis,  introducing a differential 
diagnosis of psychiatric disease.
Pathogenic Mechanisms
Anti-NMDAR encephalitis appears to be triggered 
by the presence of a tumor,  mostly an ovarian teratoma 
that contains nervous system tissue and expresses 
NMDAR [12].  The autoantibodies are present in 
patients’ serum and cerebrospinal fluid (CSF),  which 
usually show intrathecal synthesis and high antibody 
concentration [4].  NMDARs are heteromers of NR1 
subunits that bind glycine and NR2 subunits that bind 
glutamate [13].  All patients’ antibodies recognize the 
N-terminal extracellular domain of NR1,  suggesting an 
antibody-mediated pathogenesis [4 , 14].  Anti-NMDAR 
encephalitis is caused mainly by internalization of 
NMDAR without complement activation [3-5].  
Internalization of NMDAR occurs through antibody 
binding,  capping,  and cross-linking of the receptors,  
and loss of the NMDAR from the cell surface correlates 
with antibody titer [12].  Decreased synaptic NMDAR 
content leads to reduced synaptic plasticity,  as demon-
strated by the report that treatment of rodent neurons 
with patient CSF blocks molecular signatures of long-
term potentiation in the hippocampus [15].  A previous 
study found that prolonged cerebroventricular infusion 
of patient antibodies into mice results in progressive 
memory deficits,  anhedonia,  and depression-like 
behaviors [16].  After stopping the infusion of antibod-
ies,  there was progressive clinical improvement associ-
ated with restoration of NMDAR levels [17].
Epidemiology
The exact incidence of anti-NMDAR encephalitis is 
unknown,  but the number of case reports seems to be 
more frequent than any other known paraneoplastic 
encephalitis [3].  A recent review with demographic 
analyses in 633 patients has shown that the median age 
of disease onset was 22.6 years (range 8 months to 84 
years),  and that patients consisted of 492 females 
(77.8%) and 141 males (22.2%) [6].  A viral prodrome,  
such as headache (75 cases) and fever (56 cases),  at the 
onset of symptoms was documented in 133 cases 
(21.0%) [6].  Among all patients,  ovarian teratoma was 
documented in 178 cases (28.1%) and other malignant 
neoplasms in 28 cases (4.4%) [6].  The teratoma-associ-
ated cases were significantly more likely to present with 
psychiatric symptoms and have psychosis and auto-
nomic symptoms than those without teratoma [6].  
However,  it is still unknown whether tumors other than 
teratomas are truly pathogenic of the illness or unre-
lated coincident disorders [3].
Symptoms and Clinical Course
Patients with anti-NMDAR encephalitis present var-
ious symptoms [18].  In a systematic review in 633 
patients with anti-NMDAR encephalitis,  the symptoms 
during the course of illness were behavioral (80.3%),  
neurological (75.5%),  seizures (63.2%),  autonomic 
(51.3%),  psychotic (45.8%),  and cognitive (43.9%) [6].  
Among the psychiatric symptoms,  the most common 
were abnormal behaviors (e.g.  agitated,  bizarre,  or cry-
ing) (80.3%),  abnormal speech (e.g.  mute or echolalia) 
(50.4%),  catatonia (32.7%),  hallucinations (31.3%),  
insomnia (23.4%),  mood (24.5%),  and delusions 
(20.5%) [6].  In the previous review in 571 patients with 
anti-NMDAR encephalitis,  23 (4%) developed isolated 
psychiatric symptoms [19].
Symptoms progress over a period of days or weeks,  
with the exception of some patients with anti-NMDAR 
encephalitis [18 , 20].  Patients progress through in sev-
eral stages of illness and recovery,  as first reported by 
Iizuka et al.  [21].  They asserted that the clinical course 
of typical patients sequentially progressed through five 
phases: prodromal,  psychotic,  unresponsive,  hyper-
kinetic,  and gradual recovery.  In the prodromal phase,  
most patients presented with headache,  low-grade 
fever,  or a non-specific viral-like illness within 2 weeks 
before hospital admission [4 , 21].  It is unknown 
whether the prodromal symptoms form part of an early 
immune activation,  or result from a non-specific infec-
tion that facilitates crossing of the blood-brain barrier 
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by the immune response [4].  In the psychotic phase,  
patients had emotional disturbances (e.g.,  apathy,  lack 
of emotion,  depression,  loneliness,  or fear),  cognitive 
decline,  and prominent schizophrenia-like symptoms,  
including disorganized thinking,  compulsive ideation,  
delusions,  hallucinations,  and loss of self-awareness 
[21 , 22].  In this phase,  most patients had seizures,  
reduced verbal output,  and developed decreased con-
sciousness [4 , 20].  In the unresponsive phase,  patients 
were mute,  akinetic,  and unresponsive to verbal com-
mands while keeping their eyes open,  resembling cata-
tonia [23].  They also presented bizarre and inappropri-
ate smiling,  athetoid dystonic postures,  echo 
phenomenon,  and catalepsy-like symptoms [4 , 21].  In 
the hyperkinetic phase,  patients gradually developed 
orolingual dyskinesia such as lip licking or chewing,  
and athetoid dystonic postures of the fingers [21].  At 
this stage,  most patients had symptoms of autonomic 
instability,  including labile blood pressure,  bradycardia 
or tachycardia,  hyperthermia,  and diaphoresis,  and 
some patients developed central hypoventilation,  
requiring ventilator support [4 , 21 , 22].  The recovery 
phase from this disorder is typically slow and gradual 
after immunotherapy or anti-inflammatory therapy [3].
More than 75% of all patients eventually have sub-
stantial recovery that occurs in inverse order of symp-
tom development,  and the decline of anti-NMDAR 
antibody titers could be associated with the abatement 
of neurological symptoms [3 , 18].  However,  a recent 
study did not find the association between the antibody 
titers and psychiatric symptoms [24].
Diagnostic Tests and Criteria
A majority of patients with anti-NMDAR encephali-
tis show abnormal findings on magnetic resonance 
imaging (MRI),  electroencephalogram (EEG),  or CSF 
[6].  In 706 patients with anti-NMDAR encephalitis,  
MRI was abnormal in 35.6%,  EEG abnormal in 83.0%,  
and CSF abnormal in 76.4% [6].  In MRI findings,  T2 or 
fluid attenuated inversion recovery (FLAIR) signal 
hyperintensity could be seen in the hippocampi,  cere-
bellar or cerebral cortices,  frontobasal and insular 
regions,  basal ganglia,  or brainstem [3 , 6].  A recent 
systematic review of MRI findings in anti-NMDAR 
encephalitis also demonstrated that the most common 
abnormal findings are T2/FLAIR medial temporal and 
frontal hyperintensity and leptomeningeal contrast 
enhancement [25].  In EEG,  non-specific,  slow,  and 
disorganized activity was seen in most patients [3 , 6].  
However,  some patients occasionally showed a unique 
EEG pattern named “extreme delta brush”,  character-
ized by rhythmic delta activity at 1-3 Hz with superim-
posed bursts of rhythmic 20-30 Hz beta frequency 
activity riding on each delta wave [26].  Slow,  continu-
ous,  rhythmic activity in the delta-theta range predom-
inates in the catatonic-like stage [27].  In CSF findings,  
moderate lymphocytic pleocytosis,  normal or mildly 
increased protein concentration,  and CSF-specific oli-
goclonal bands were seen in many patients [3 , 6].
Graus et al.  have currently presented the diagnostic 
criteria for anti-NMDA receptor encephalitis [28].  For 
the diagnosis of “probable” anti-NMDAR encephalitis,  
all of the below criteria is required: 1) at least three of 
the six clinical symptoms (abnormal behavior or cogni-
tive dysfunction,  speech dysfunction,  seizures,  move-
ment disorder/dyskinesia/rigidity/abnormal postures,  
decreased level of consciousness,  and autonomic dys-
function/central hypoventilation) accompanied by a 
systemic teratoma,  2) at least one of the laboratory 
study results (abnormal findings on EEG,  such as focal 
or diffuse slow or disorganized activity,  epileptic activ-
ity,  or extreme delta brush,  and in abnormal CSF find-
ings,  such as pleocytosis or oligoclonal bands,  and 3) 
reasonable exclusion of other disorders.  For the diag-
nosis of “definite” anti-NMDAR encephalitis,  diagnosis 
can be made in the presence of one or more of the 6 
symptoms and IgG anti-GluN1 antibodies after reason-
able exclusion of other disorders.  Antibody testing 
should include CSF analysis because anti-NMDAR 
antibody-testing is more sensitive in CSF than serum 
[29].
Treatment and Outcomes
In 2011,  Dalmau et al.  proposed the algorithm for 
the treatment of anti-NMDAR encephalitis,  that has 
been widely used [3].  They recommended that anti-
body studies be done on both serum and CSF for 
patients suspected of anti-NMDAR encephalitis because 
periodic screening of serum and CSF is useful to assess 
the effects of treatment,  especially in the central ner-
vous system [3 , 5].  Antibody-positive patients should 
be examined for the presence of an underlying tumor,  
mainly an ovarian teratoma or a testicular germ-cell 
tumor [3 , 5 , 30].  After removal of underlying tumors,  
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if any,  first-line immunotherapy consists of methyl-
prednisolone,  intravenous immunoglobulins and 
plasma exchange given alone or in combination [3 , 30].  
If no response to first-line therapy is seen after 10 days,  
second-line immunotherapy,  consisting of rituximab,  
cyclophosphamide,  or both is recommended [3 , 30].  
Substantial improvement was defined as full recovery or 
minimum deficits estimated by physicians and family 
members as recovery of more than 90% of function [4].  
All other patients are judged to have little improvement 
or no change [5].  The process of recovery happens in 
the reverse order of symptom presentation,  and recov-
ery can be incomplete or delayed by many months 
[3 , 30].  Dalmau et al.  showed that 81 (77%) of 105 
patients had substantial improvement,  and five patients 
(5%) died [3].  In the long-term cohort study of patients 
with anti-NMDAR encephalitis,  394 (79%) of 501 
patients achieved a good outcome and 30 (6%) died 
during the first 24 months [5].  The study indicated that 
predictors of good outcome were early treatment and no 
admission to an intensive care unit.  Furthermore,  cur-
rent study has developed a grading score,  called the 
“NEOS score”,  that predicts neurologic function 1 year 
after diagnosis of anti-NMDAR encephalitis and con-
sists of five variables: intensive care unit admission,  
treatment delay > 4 weeks,  lack of clinical improvement 
within 4 weeks,  abnormal MRI,  and CSF white blood 
cell count > 20 cells/μl [31].  This score could help esti-
mate the clinical course following diagnosis.
Whereas many studies have reported the effective-
ness of immunotherapy,  little study has investigated the 
effects of antipsychotics for anti-NMDAR encephali-
tis-induced psychiatric symptoms.  A current review 
included 159 cases of anti-NMDAR encephalitis treated 
with antipsychotics,  including haloperidol (36.5%),  
risperidone (25.8%),  olanzapine (23.3%),  quetiapine 
(13.2%),  and aripiprazole (6.9%) [6].  Antipsychotics 
were stopped due to suspected neuroleptic malignant 
syndrome in 42 cases,  and the effectiveness of anti-epi-
leptics was inconsistent [6].  Since treatment of psychi-
atric symptoms of anti-NMDAR encephalitis is compli-
cated by resistance to traditional psychotropic agents,  
electroconvulsive therapy (ECT) may be of use in 
refractory cases.  A current systematic review of ECT 
cases showed that there was improvement of psychiatric 
symptoms in 65.2% of cases,  and there was no compli-
cation in 86.7% of cases,  with four cases prematurely 
ceasing ECT with further encephalitic deterioration 
[32].  ECT can be an effective and safe adjuvant treat-
ment for refractory psychiatric symptoms in anti-
NMDAR encephalitis.
Differential Diagnosis from Schizophrenia
Many patients with anti-NMDAR encephalitis visit 
psychiatric institutions first due to the prominence of 
psychiatric symptoms as the initial symptoms [33].  
Several studies have shown that approximately 80% of 
patients with anti-NMDAR encephalitis were initially 
seen by psychiatrists [4 , 7].  The mechanisms underly-
ing psychotic symptoms of anti-NMDAR encephalitis 
may support the glutamate hypothesis of schizophrenia 
[34].  The glutamate hypothesis of schizophrenia is 
founded largely on the similarity of psychotic symptoms 
associated with NMDAR antagonists such as phencycli-
dine and ketamine [35 , 36].  Anti-NMDAR encephalitis 
demonstrates that NMDAR hypofunction results not 
only in psychosis,  but also in cognitive impairment,  
mood changes,  and other symptoms of schizophrenia 
[33].  Furthermore,  the link between infection and 
schizophrenia has suggested the involvement of immu-
nologic processes [37].  Prior to discovery of anti-
NMDAR encephalitis,  Bechter hypothesized that 
schizophrenia is a “mild encephalitis” because many 
patients with schizophrenia exhibited symptoms 
beyond psychosis (cognitive impairment,  catatonia,  
and autonomic dysfunction) though pathognomonic 
auto-antibodies remain elusive [38].  Anti-NMDAR 
encephalitis is often preceded by prodromal symptoms 
suggesting a viral process,  and that the viral process can 
develop into an immune-mediated dysfunction of syn-
aptic transmission [39].
Several studies demonstrated the prevalence of anti-
NMDAR antibodies in patients with schizophrenia.  
Steiner et al.  investigated the prevalence of anti-NMDAR 
antibodies in serum of patients with acute schizophre-
nia (N = 121) and healthy controls (N = 230),  identify-
ing anti-NMDAR antibodies in 15 subjects,  primarily 
those with an initial schizophrenia diagnosis (12 of 121,  
9.9%) and controls (1 of 230,  0.4%) [8].  They also 
investigated the prevalence with additional samples,  
and anti-NMDAR antibodies were identified in schizo-
phrenia (18 of 184,  9.9%) and controls (25 of 357,  
7.0%) [40].  The prevalence of anti-NMDAR antibodies 
(any immunoglobulin isotype) in patients with schizo-
phrenia was reported to be 8.6% (93 of 1,081),  almost 
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identical to that of healthy controls (137 of 1,272,  
10.8%) [41].  The isotype analysis in this study indicated 
that NR1 IgG antibodies are extremely uncommon and 
that IgA or IgM antibodies are frequent.  In contrast to 
IgG antibodies,  which are highly specific to anti-
NMDAR encephalitis,  the clinical significance of IgA 
and IgM antibodies is uncertain [42].  Hara et al.  also 
indicated that IgG antibodies were highly specific for 
anti-NMDAR encephalitis and caused a decrease of the 
levels of NMDAR,  but that IgA or IgM antibodies 
occurred nonspecifically and did not alter the receptor 
levels [43].
A recent study has shown the prevalence of anti-
NMDAR antibodies in patients with early psychosis.  In 
the study of first-episode psychosis,  3 of 46 patients had 
anti-NMDAR antibodies in their serum (6.5%) [44],  
and another study reported that 7 of 228 patients were 
seropositive (3%).  [45].  In addition,  it was reported 
that no patient with first-episode psychosis had anti-
NMDAR antibodies (0 of 70),  but 1 patient of 6 with a 
clinical high risk for psychosis was seropositive,  
although antibodies were not found in his CSF [46].  
Nevertheless,  there has been no study investigating 
anti-NMDAR antibodies in CSF,  rather than serum,  of 
patients with psychiatric illness.  Although the evalua-
tion procedure is invasive,  further studies investigating 
the antibodies in CSF would be important since anti-
NMDAR antibody-testing is more significant in CSF 
than serum [29].
Differential Diagnosis of Mood Disorder
Like schizophrenia,  the pathophysiology of mood 
disorder is associated with dysfunction of the glutama-
tergic system,  such as malfunction of clearance and 
metabolism of glutamate [47 , 48].  A number of studies 
have demonstrated that environmental stress induces an 
increase in glutamate release in various brain areas,  and 
an excess of synaptic glutamate causes neurotoxicity 
[49 , 50].  Patients with mood disorder have dysregula-
tion of the glutamine/glutamate cycle and significantly 
higher glutamine levels in serum and CSF as compared 
to normal controls [51 , 52].  At the molecular level,  
expression of NMDA glutamate receptors as well as glu-
tamate transporter have been found to be altered in 
postmortem brain tissue from patients with mood dis-
order [53].  Moreover,  ketamine,  one of the NMDAR 
antagonists,  has been reported to have an anti-depres-
sant effect [54 , 55],  even in treatment-resistant mood 
disorders [56].  Memantine,  a low-affinity NMDAR 
antagonist,  is also reported to have a significant effect in 
patients with treatment-resistant mood disorders [57].
In spite of this evidence that demonstrated altered 
glutamatergic neurotransmission in mood disorders,  
there have been few studies of the relationships between 
anti-NMDAR encephalitis and mood disorders.  In 
addition,  the isotypes of anti-NMDAR autoantibodies 
showed a broader distribution like schizophrenia.  The 
prevalence of anti-NMDAR antibodies in the serum of 
patients with depression has been reported: 5.1% (5 of 
99) in any immunoglobulin isotype,  but 0% (0 of 99) in 
the IgG isotype [40] .  In another study of patients with 
affective disorders,  16.2% (24 of 148) were seropositive 
in any immunoglobulin isotype,  but only 3.4% (5 of 
148) in IgG [41].  Since there have been no studies 
investigating relationships between anti-NMDAR 
encephalitis and mood disorder using CSF examina-
tion,  further studies will be required for patients with 
mood disorder,  just like schizophrenia.
Conclusion
In this review,  we evaluated anti-NMDAR encepha-
litis from the perspective of psychiatry.  When psychia-
trists occasionally examine patients with anti-NMDAR 
encephalitis in psychiatric institutions,  we recommend 
that psychiatrists should be aware of the following three 
points: 1) subacute clinical course through 5 phases 
(prodromal,  psychotic,  unresponsive,  hyperkinetic,  
and gradual recovery),  2) presence of neurological fea-
tures such as orolingual dyskinesia,  and 3) abnormal 
findings in CSF,  EEG and MRI.  Anti-NMDAR enceph-
alitis may contribute to our understanding of the inter-
action between psychosis,  autoimmunity,  and gluta-
matergic function.  Since the majority of patients with 
anti-NMDAR encephalitis visit psychiatric institutions 
at the beginning of illness,  psychiatrists must cultivate 
a better understanding of anti-NMDAR encephalitis.
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